Volume 20 Issue 5
May  2022
Turn off MathJax
Article Contents
ZHANG Gui-bing, HE Zheng-fei, SHANG Wen-zhong, WANG Ai-wei, WU Yan-fang, HUANG Hui-yan. Effect of triethanolamine on the biological characteristics of diffuse large B-cell lymphoma cells[J]. Chinese Journal of General Practice, 2022, 20(5): 785-788. doi: 10.16766/j.cnki.issn.1674-4152.002454
Citation: ZHANG Gui-bing, HE Zheng-fei, SHANG Wen-zhong, WANG Ai-wei, WU Yan-fang, HUANG Hui-yan. Effect of triethanolamine on the biological characteristics of diffuse large B-cell lymphoma cells[J]. Chinese Journal of General Practice, 2022, 20(5): 785-788. doi: 10.16766/j.cnki.issn.1674-4152.002454

Effect of triethanolamine on the biological characteristics of diffuse large B-cell lymphoma cells

doi: 10.16766/j.cnki.issn.1674-4152.002454
Funds:

 2020ZA098

  • Received Date: 2021-05-28
    Available Online: 2022-09-05
  •   Objective  To observe the effect of triethanolamine (TEOA) on the biological characteristics of diffuse large B-cell lymphoma (DLBCL) cells, so as to provide a basis for clinical treatment of the disease.  Methods  DLBCL cell lines OCI-LY3 were provided by the cell bank of the Chinese Academy of Sciences. They were randomised into the control group and observation group by random number table method, with five parallel holes in each group. Different concentrations (5, 10, 15, 20, 25, 30, 35, 40, 45, 50 μmol/L) of TEOA were added into the observation group and then cultured for 12 h. The GraphPad Prism 5 software was used to calculate the survival rates of DLBCL cells in both groups, flow cytometry was used to detect the apoptosis and invasion of DLBCL cells, the MTT method was used to detect the proliferation of DLBCL cells, and Western Blotting was used to detect the relative protein expression. The levels of reactive oxygen species (ROS) in both groups were compared, and research data were collected and input into the SPSS 20.0 statistical software for statistical analysis.  Results  After 24, 48 and 72 h of TEOA treatment, the cell proliferation rates in the observation group[(39.24±3.95)%, (57.08±5.87)% and (114.08±14.69)%] were significantly lower than those in the control group[(49.49±5.02)%, (95.12±9.64)% and (210.45±25.62)%, all P < 0.05]. The observation group had significantly smaller number of transmembrane cells (38.14±3.77) and significantly higher apoptosis rate[(12.14±1.24)%] than the control group[92.25±9.24 and (3.64±0.36)%, respectively, all P < 0.05]. TEOA could increase ROS levels in DLBCL OCI-LY3 cells and effectively upregulate the expression levels of p38, p-Chk1, p-Chk2 and γ-H2AX in OCI-LY3.  Conclusion  TEOA can inhibit cell proliferation and invasion whilst effectively inducing cell apoptosis and ROS expression. TEOA acting on DLBCL OCI-LY3 cells can promote the expression of p38, p-Chk1, p-Chk2 and γ-H2AX and induce the activation of the p38 MAPK pathway.

     

  • loading
  • [1]
    金静霞, 郑翠苹, 陈丽雅, 等. PD-1、PD-L1在弥漫大B细胞淋巴瘤组织中的差异性表达及其临床意义[J]. 临床血液学杂志, 2018, 31(1): 34-37. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ201801011.htm

    JIN J X, ZHENG C P, CHEN L Y, et al. The differential expression levels and clinical significance of PD-1 and PD-L1 in tumor tissues of diffuse large B cell lymphoma[J]. Journal of Clinical Hematology, 2018, 31(1): 34-37. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ201801011.htm
    [2]
    王友群, 唐小万. CHOP方案联合美罗华治疗弥漫大B细胞淋巴瘤78例回顾性分析[J]. 中华全科医学, 2018, 16(6): 916-918. doi: 10.16766/j.cnki.issn.1674-4152.000251

    WANG Y Q, TANG X W. A retrospective analysis of 78 cases of diffuse large B-cell lymphoma treated with CHOP chemotherapy regimen combined with rituximab[J]. Chinese general practice, 2018, 16(6): 916-918. doi: 10.16766/j.cnki.issn.1674-4152.000251
    [3]
    CHEN T, YUAN Y, HUANG L S, et al. Dominant-negative PD1-armored CART cells induce remission in refractory diffuse large B-cell lymphoma (DLBCL) patients[J]. J Clin Oncol, 2019, 37(15): e19028.
    [4]
    KHURANA A, MWANGI R, NOWAKOWSKI G S, et al. Impact of organ function based standard exclusion criteria in diffuse large b-cell lymphoma (DLBCL) patients: Who gets left behind?[J]. J Clin Oncol, 2020, 38(15_suppl): e14100.
    [5]
    MONDELLO P, MIAN M. Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP[J]. Hematol Oncol, 2019, 37(4): 333-344.
    [6]
    王怡, 夏冰, 张翼鷟. 复发/难治性弥漫大B细胞淋巴瘤的分子诊疗进展[J]. 中国实验血液学杂志, 2018, 26(2): 603-608. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201802054.htm

    WANG Y, XIA B, ZHANG Y Z. Therapeutic progress in relapse/refractory diffuse large-B-cell lymphoma[J]. Journal of Experimental Hematology, 2018, 26(2): 603-608. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201802054.htm
    [7]
    李晓阳, 吴志平, 王梦馨, 等. 表没食子儿茶素没食子酸酯抗癌分子机制及其应用的研究进展[J]. 中草药, 2019, 50(13): 3217-3229.

    LI X Y, WU Z P, WANG M X, et al. Research progress on molecular mechanism of epigallocatechin-3-gallate against cancer and its application[J]. Chinese Traditional and Herbal Drugs, 2019, 50(13): 3217-3229.
    [8]
    张丹丹. TEOA抗人结肠癌细胞作用机制的初步研究[D]. 杭州: 浙江大学, 2017.

    ZHANG D D. Preliminary study on the mechanism of TEOA against human colon cancer cells[D]. Hangzhou: Zhejiang University, 2017.
    [9]
    DUBOIS S, JARDIN F. Novel molecular classifications of DLBCL[J]. Nat Rev Clin Oncol, 2018, 15(8): 474-476.
    [10]
    KAPADIA B, NANAJI N M, BHALLA K, et al. Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL[J]. Nat Commun, 2018, 9(1): 829.
    [11]
    林剑扬, 郑艳彬, 何鸿鸣, 等. DLBCL的临床病理特征及影响预后的相关因素分析[J]. 中国实验血液学杂志, 2018, 26(3): 779-783. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201803027.htm

    LIN J Y, ZHENG Y B, HE H M, et al. Clinicopathological features and prognostic factors of DLBCL[J]. Journal of Experimental Hematology, 2018, 26(3): 779-783. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201803027.htm
    [12]
    葛超, 吕梦迪, 张自由, 等. 基于天然产物的铂类和芳基金属抗癌药物研究进展[J]. 无机化学学报, 2020, 36(4): 597-606. https://www.cnki.com.cn/Article/CJFDTOTAL-WJHX202004002.htm

    GE C, LYU M D, ZHANG Z Y, et al. Trends of platinum and metal-arene anticancer drugs based on natural products[J]. Chinese Journal of Inorganic Chemistry, 2020, 36(4): 597-606. https://www.cnki.com.cn/Article/CJFDTOTAL-WJHX202004002.htm
    [13]
    TANG B, HUO Z, WU P. Study on a novel polyester composite nanofiltration membrane by interfacial polymerization of triethanolamine (TEOA) and trimesoyl chloride (TMC): I. Preparation, characterization and nanofiltration properties test of membrane[J]. J Membr Sci, 2008, 320: 198-205.
    [14]
    韩波, 高志棣, 王海霞, 等. miR-155在弥漫大B细胞淋巴瘤组织中的表达及其对细胞生物学特性的影响[J]. 中国实验血液学杂志, 2019, 27(2): 445-451. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201902026.htm

    HAN B, GAO Z L, WANG H X, et al. Expression of miR-155 in tissue of patients with diffuse large B-cell lymphoma and its effect on cell biological characteristics[J]. Journal of Experimental Hematology, 2019, 27(2): 445-451. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201902026.htm
    [15]
    岳文君, 刘勇军, 陈京涛. NF-κB信号通路在弥漫大B细胞淋巴瘤中的作用及其靶向治疗中的应用[J]. 中国肿瘤生物治疗杂志, 2020, 27(1): 68-75. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202001012.htm

    YUE W J, LIU Y J, CHEN J T. The role of NF-κB signaling pathway in diffuse large B cell lymphoma and its application in targeted therapy[J]. Chinese Journal of Cancer Biotherapy, 2020, 27(1): 68-75. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202001012.htm
    [16]
    FU S, LUAN T, JIANG C Y, et al. miR-3622a promotes proliferation and invasion of bladder cancer cells by downregulating LASS2[J]. Gene, 2019, 701: 23-31.
    [17]
    刘靖, 杨画, 寻阳, 等. sCXCL16对弥漫大B细胞淋巴瘤的体外生物学影响与初步机制[J]. 临床与实验病理学杂志, 2019, 35(4): 393-397. https://www.cnki.com.cn/Article/CJFDTOTAL-LSBL201904004.htm

    LIU J, YANG H, XUN Y, et al. Effect of soluble CXCL16 on diffuse large B cell lymphoma in vitro and its preliminary mechanism[J]. Chinese Journal of Clinical and Experimental Pathology, 2019, 35(4): 393-397. https://www.cnki.com.cn/Article/CJFDTOTAL-LSBL201904004.htm
    [18]
    胡施炜, 楼恩哲, 王瑜, 等. 大黄酸通过抑制NF-κB通路促进DLBCL细胞OCI-LY8凋亡[J]. 中国病理生理杂志, 2019, 35(11): 1974-1980. https://www.cnki.com.cn/Article/CJFDTOTAL-ZBLS201911008.htm

    HU S W, LOU E Z, WANG Y, et al. Rhein promotes DLBCL cell OCI-LY8 apoptosis by inhibiting NF-κB signaling pathway[J]. Chinese Journal of Pathophysiology, 2019, 35(11): 1974-1980. https://www.cnki.com.cn/Article/CJFDTOTAL-ZBLS201911008.htm
    [19]
    HOJJAT-FARSANGI M, GHADERI A, DANESHMANESH A H, et al. Diffuse large B cell lymphoma (DLBCL) expresses ROR1 and a ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of tumor cells[J]. Blood, 2019, 134(Suppl 1): 2565.
    [20]
    余醒醒. TEOA通过激活ROS依赖的p38MAPK信号通路抑制弥漫性大B细胞淋巴瘤细胞的增殖并诱导其DNA损伤[D]. 蚌埠: 蚌埠医学院, 2019.

    YU X X. TEOA inhibits proliferation and induces DNA damage of diffuse large B-cell lymphoma cells by activating ROS-dependent p38MAPK signaling pathway[D]. Bengbu: Bengbu Medical College, 2019.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Article Metrics

    Article views (221) PDF downloads(3) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return